跳至主要内容
临床试验/ACTRN12619000311156
ACTRN12619000311156招募中1 期

Ketamine Therapy For Internalizing Disorders: Is There A Single Mechanism?

niversity of Otago0 个研究点目标入组 48 人开始时间: 2019年2月28日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
All

入选标准

  • Capable of understanding and signing an informed consent
  • diagnosed with one of the following DSM-5 diagnoses:
  • -post-traumatic stress disorder (PTSD) with a CAPS score >60;
  • -obsessive-compulsive disorder (OCD) with a YBOCS score >26;
  • -major depressive disorder (MDD) with a MADRS score >20;
  • -phobic state with FQ18 score >6
  • Patients with PTSD, OCD or phobic state must not have MADRS scores >20 at screening.
  • Patients must have had an inadequate response to prior treatment i.e. have not responded to at least two adequate trials of relevant medication and at least one trial of relevant psychotherapy.

排除标准

  • evidence of severe acute or chronic medical disorders,
  • past or current diagnoses of schizophrenia, bipolar disorder, or current psychotic symptoms
  • female patients who are pregnant or lactating
  • drug use or dependence in the last 6 months
  • current significant suicidal ideation
  • prior history of seizures; susceptibility to photosensitivity; or a history of allergic skin reactions

研究者

相似试验

Ketamine and Internalizing Disorders | 临床试验